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Abstract
Metformin (dimethylbiguanide) has been found to be effective for the treatment of a wide range of 
cancer. Herein, a novel lipid (1,2-di-(9Z-octadecenoyl)-3-biguanide-propane (DOBP)) was 
elaborately designed by utilizing biguanide as the cationic head group. This novel cationic lipid 
was intended to act as a gene carrier with intrinsic antitumor activity. When compared with 1,2-di-
(9Z-octadecenoyl)-3-trimethylammonium-propane (DOTAP), a commercially available cationic 
lipid with a similar structure, the blank liposomes consisting of DOBP showed much more potent 
antitumor effects than DOTAP in human lung tumor xenografts, following an antitumor 
mechanism similar to metformin. Given its cationic head group, biguanide, DOBP could 
encapsulate TNF-related apoptosis-inducing ligand (TRAIL) plasmids into Lipid-Protamine-DNA 
(LPD) nanoparticles (NPs) for systemic gene delivery. DOBP-LPD-TRAIL NPs demonstrated 
distinct superiority in delaying tumor progression over DOTAP-LPD-TRAIL NPs, due to the 
intrinsic antitumor activity combined with TRAIL-induced apoptosis in the tumor. These results 
indicate that DOBP could be used as a versatile and promising cationic lipid for improving the 
therapeutic index of gene therapy in cancer treatment.
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1. Introduction
Gene therapy is an efficient therapeutic strategy for cancer treatment [1]. However, 
intravenous delivery of nucleic acid based bioactive agents is still a major challenge. Viral 
gene carriers have long been criticized for their potential risk of immunogenicity and 
toxicity [2]. Non-viral systems may offer safer profiles and hold great potential for systemic 
gene delivery, but favorable clinical outcomes are still a long way off, primarily due to 
ineffective delivery mechanisms [2,3].
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The TNF-related apoptosis-inducing ligand (TRAIL) is a good candidate for cancer therapy 
due to its specific antitumor activity, which reduces risk to normal cells [4]. TRAIL has 
exhibited potent antitumor activity against a variety of tumors by inducing apoptosis in 
tumor cells, including human non-small-cell lung cancer (NSCLC) [4,5]. In addition to its 
strong antitumor activity, TRAIL presents no systemic toxicity in animals [6]. TRAIL-
induced apoptosis is mediated by the death receptor pathway in tumor cells [7]. The binding 
of TRAIL to death domain-containing receptors on the cell surface will lead to the caspase-
dependent irreversible apoptosis [7]. However, the application of TRAIL in cancer therapy is 
greatly limited by its short half-life in vivo [8]. Additionally, although TRAIL-targeted 
therapy holds great potential for cancer treatment, the clinical results of TRAIL have shown 
limitations, including inefficient delivery to tumor site, the complexity of the pathways, and 
resistance mechanisms [9]. Therefore, it is necessary to develop suitable nano-sized vehicles 
for TRAIL systemic delivery.
Metformin (dimethylbiguanide) is commonly used for patients with type II diabetes mellitus 
[10]. This cationic drug has well-established efficacy and a good safety profile, even at doses 
as high as 2 g/day, due to its very low toxicity [10]. More interestingly, metformin 
demonstrated significant antitumor activity against a wide range of cancers, including 
human NSCLC [10]. In our previous study, a cationic polymer of metformin (PolyMet) with 
intrinsic antitumor activity and low toxicity was designed and applied in siRNA delivery 
[11]. The biguanide groups of PolyMet can be used simultaneously as the cationic blocks for 
gene condensation and the chemotherapeutic agent for cancer treatment [11].
Designing carrier materials with intrinsic antitumor activity is an ideal strategy for cancer 
therapy. Therefore, we further hypothesized that biguanide could also be utilized as the 
cationic head group for a new cationic lipid, similar to 1,2-di-(9Z-octadecenoyl)-3-
trimethylammonium-propane (DOTAP, a commercially available cationic lipid). Based on 
this rationale, we designed a DOTAP-like cationic lipid by changing the 
trimethylammonium of DOTAP to biguanide (Fig. 1A), namely 1,2-di-(9Z-octadecenoyl)-3-
biguanide-propane (DOBP). DOBP was developed as a promising cationic lipid with 
intrinsic antitumor activity to facilitate gene therapy in cancer treatment. The biguanide 
group of DOBP acted similarly to metformin and perform antitumor activity by activating 
the AMPK signaling pathway [10]. And several studies have indicated that activation of 
AMPK signaling pathway could significantly sensitize TRAIL-induced apoptosis of human 
tumor cells [12–14]. Based on this rationale, we used a well-established Lipid-Protamine-
DNA (LPD) formulation [15] to test the antitumor efficacy of the TRAIL plasmid DNA 
delivered by DOBP-LPD nanoparticles (NPs) (Fig. 1B) in a NSCLC model. The combined 
effect of DOBP and TRAIL was demonstrated.
2. Experimental section
2.1. Materials
Oleic acid, N-Boc-3-amino-glycerine, hydrochloride acid solution in 1,4-dioxane, 
dicyandiamide, protamine and cholesterol were purchased from Sigma-Aldrich. 1,2-
dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) was obtained from Avanti 
Polar Lipids, Inc. (Alabaster, AL). 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-
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[methoxy(polyethyleneglycol-2000)] ammonium salt (DSPE-PEG2000) was purchased from 
NOF America Corporation. DSPE-PEG-Anisamide (DSPE-PEG-AA) was synthesized 
based on the previous established protocols [16], and DSPE-PEG-AA was used to 
specifically target to H460 cells that overexpress sigma receptors for enhanced cellular 
uptake of liposomes and LPD NPs [17]. An expression vector containing the human TRAIL 
open reading frame was purchased from InvivoGen (San Diego, CA). Primers for PCR and 
qPCR were purchased from Integrated DNA.
2.2. Synthesis of DOBP
2.2.1. Synthesis of 1,2-di-(9Z-octadecenoyl)-3-amino-propane (DOAP)—Oleic 
acid (3 mmol) was dissolved in 20 mL of dichloromethane, then N-Boc-3-amino-glycerine 
(1 mmol), EDC (3 mmol) and DMAP (3 mmol) were added. The reaction mixture was 
stirred at 25 °C for 24 h under nitrogen. Post-reaction, N-Boc-DOAP was obtained and 
purified by silica column chromatography (petroleum ether/ethyl acetate = 20:1). The Boc 
protection of the product was deprotected using hydrochloride acid solution in 1,4-dioxane, 
and DOAP (chloride salt) was obtained with a yield of 85%. The chemical structure of 
DOAP (chloride salt) was confirmed by nuclear magnetic resonance spectroscopy (NMR, 
400 MHz 1H NMR, BRUKER AV-400).
2.2.2. Synthesis of 1,2-di-(9Z-octadecenoyl)-3-biguanide-propane (DOBP)—
DOAP (chloride salt, 1 mmol) was dissolved in 20 mL of 1,4-dioxane, and dicyandiamide (2 
mmol) in 2 mL of DMF was added. FeCl3 (1 mmol) was utilized as catalyst. The reaction 
mixture was stirred at 70°C for 48 h under nitrogen. The reaction mixture was washed with 
5% hydrochloride acid to remove the FeCl3 and free dicyandiamide, and dried with 
anhydrous sodium sulfate. Sodium sulfate was filtered, and the solvent was evaporated under 
vacuum. DOBP (chloride salt) was purified by silica column chromatography 
(dichloromethane/methanol = 30:1) with a yield of 30%. The chemical structure of DOBP 
(chloride salt) was confirmed by nuclear magnetic resonance spectroscopy (NMR, 400 
MHz 1H NMR, BRUKER AV-400).
2.3. Preparation of liposome and LPD NPs
DOBP or DOTAP and cholesterol (1:1, mol/mol) were dissolved in chloroform and the 
solvent was evaporated under reduced pressure. The lipid film was hydrated overnight with 
distilled water to make the final concentration 10 mM DOBP or DOTAP and 10 mM 
cholesterol. The DOBP-liposome (Lipo-DOBP) and the DOTAP-liposome (Lipo-DOTAP) 
were sequentially extruded through 400 nm, 200 nm, 100 nm and 50 nm polycarbonate 
membranes (Millipore, Billerica, MA), respectively. The polyplex core of the LPD NPs was 
prepared by mixing 26 μg protamine in100 μL 5% glucose with equal volume of 50 μg 
plasmid in 5% glucose. The mixture was incubated at room temperature for 10 min before 
60 μL of Lipo-DOBP or Lipo-DOTAP (10 mmol/L each) were added. PEGylation and 
targeting modification were achieved by adding 15 mol% DSPE-PEG and DSPE-PEG-AA 
in the formulations with further performed at 60 °C for 15 min. The size and zeta potential 
were measured by using Zetasizer (Nano ZS, Malvern Co., UK). The morphology of the 
LPD NPs was observed by JEOL 100CX II transmission electron microscopy (TEM) 
(JEOL, Japan). NPs were negatively stained with 2% uranyl acetate. To investigate the 
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stability of LPD NPs under serum condition, LPD NPs were incubated in PBS (pH 7.4) 
supplemented with 5% of fetal bovine serum (FBS) for 12 h at 37 °C, and the mean diameter 
of the NPs was determined at timed intervals.
2.4. Cell culture
H460 human NSCLC cells and MRC-5 human fetal lung fibroblast cells were originally 
obtained from American Type Culture Collection (ATCC). The cells were cultured in RPMI 
1640 medium supplemented with 10% (v/v) fetal bovine serum (FBS), penicillin (100 
units/mL) and streptomycin (100 μg/mL) in a humidified atmosphere of 5% CO2 at 37 °C.
2.5. In vitro cytotoxicity of blank liposome
The in vitro cytotoxicity of metformin, Lipo-DOTAP and Lipo-DOBP was investigated by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in H460 cells and 
MRC-5. Briefly, cells were incubated in 100 μL of complete culture medium in 96-well 
plates at a density of 5000 cells/well for 24 h. After pre-incubation, the cells were exposed to 
serial dilutions of metformin, Lipo-DOTAP and Lipo-DOBP at different concentrations for 4 
h, and washed and further incubated for 48 h. The cells without any treatment were utilized 
as control.
2.6. In vitro apoptosis and necrosis assay
H460 cells were seeded into a 6-well plate (1.0×106 cells/well) for 24 h. After pre-
incubation, the cells were exposed to Lipo-DOTAP (20 and 50 μM), Lipo-DOBP (20 and 50 
μM) and PEI (1.25 and 12.5 μM) for 6 h. Then, the cells were washed with PBS and 
trypsinized. Apoptosis and necrosis analysis was evaluated according to the manufacturer’s 
protocols (Beckon Dickinson, CA). Annexin V-FITC (FL1)/PI (FL2) fluorescence signals 
were analyzed by flow cytometry on a BD FACSAria instrument (Beckon Dickinson, CA).
2.7. Cellular uptake and intracellular trafficking of DOBP-LPD NPs
For the visualization of cellular uptake and intracellular trafficking of DOBP-LPD-NPs, a 
hydrophobic dye DiI (Sigma, MO) was encapsulated into the lipid layer of the NPs. At the 
same time, Cy5 labelled DNA was prepared using Label IT® (Mirus, Madison, WI, USA) 
and encapsulated into the polyplex core of the NPs. The double labelled NPs (with or 
without AA) was then incubated with NCI-H460 cells, which were pre-seeded in LabTek 
Chambered Coverglass at a density of 5×104 cells/well. At 0.5, 2, and 6 h post incubation, 
cells were washed three times with cold DPBS and then subjected to endosome/lysosome 
and nucleus staining by incubation with Lysotracker Green (1 μg/mL) and Hoechst 33342 (5 
μg/mL), respectively. After washing with DPBS, cover slips were mounted on slides and 
examined by confocal laser scanning microscopy (Zeiss LSM 510 Meta, Germany).
2.8. Animals
Female nude mice (4–6 weeks old) were used in the animal studies. Animals were purchased 
from National Cancer Institute (Bethesda, MD) and bred by the Division of Laboratory 
Animal Medicine (DLAM) at University of North Carolina at Chapel Hill. To establish the 
H460 NSCLC xenograft models, 5×106 cells in 100 μL of PBS were injected 
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subcutaneously into the right flank of the mice. All animal studies were carried out 
according to the protocols approved by the University of North Carolina at Chapel Hill’s 
Institutional Animal Care and Use Committee.
2.9. In vivo antitumor activity of blank liposomes
Human H460 NSCLC cells (5×106 cells/100 μL) in PBS were inoculated subcutaneously 
into the female nude mice. When the tumor size was approximately 80 mm3, H460 
xenografts tumor-bearing nude mice were randomized to four groups (five mice per group): 
untreated control (PBS), metformin solution, Lipo-DOTAP and Lipo-DOBP. The mice 
received treatment through tail veins every other day for a total of 5 injections with an 
equivalent metformin dose of 5 mg/kg. Lipo-DOBP and Lipo-DOTAP were administrated at 
an equivalent molar dose of metformin (30 μmol/kg of DOBP or DOTAP). Tumor volume 
and body weight were measured every day. Mice were sacrificed one day after the last 
injection, and serum was collected for hepatic and renal function analysis.
2.10. Western-Blot analysis
Tumor samples were lysed by a Radio-Immunoprecipitation Assay (RIPA) buffer. A 
bicinchoninic acid (BCA) assay (Invitrogen, CA) was used to determine the protein 
concentration in the tumors according to the manufacturer’s protocols. The protein solution 
was diluted by sample buffer (4×) containing reducing reagent and heated at 95 °C for 5 
min. Protein was separated by 4%–12% SDS-PAGE electrophoresis (Invitrogen), and then 
transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad). The membranes 
were blocked with 5% non-fat dry milk (Bio-Rad) at room temperature for 1 h and then 
incubated with primary antibodies overnight at 4 °C. The membranes were washed and 
further incubated with a secondary antibody (1:4000 dilution) at room temperature for 1 h, 
and then detected using the Pierce ECL Western Blotting Substrate (Thermo Fisher 
Scientific, IL). GAPDH was used as the control.
2.11. Pharmacokinetics and biodistribution of LPD NPs
A trace amount of 3H labelled cholesteryl hexadecyl ether (PerkinElmer, MA) were mixed 
with other lipids while preparing the liposomes. Mice were injected IV via the tail vein 
with 3H-labelled DOBP-LPD NPs or DOTAP-LPD NPs (with same 3H levels, n = 3). At 5 
min, 15 min, 30 min, 1, 2, 4, 8, 16, 24 h post-injection, blood samples were collected from 
the saphenous vein using a heparinized capillary tube. The mice were sacrificed after 
endpoint (24 h) and major organs were collected afterwards. Ten to 20 mg of blood, or ~100 
mg tissues were immediately mixed with 10 × NCS® II Tissue Solubilizer (Amersham 
Biosciences, Inc) and digested at 60 °C overnight. Two hundred μL of hydrogen peroxide 
(30% in water, Fisher) was added to the samples and vortexed to bleach the color, and the 
sample was then mixed with 4 mL scintillation cocktail (Fisher Inc). The 3H radioactivity in 
the blood and tissue samples were counted using a liquid scintillation analyzer (TRI-CARB 
2900 TR, Packard Bioscience Co.).
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2.12. In vivo antitumor activity of LPD NPs
Human H460 NSCLC xenograft was constructed by the same methods in female nude mice. 
GFP plasmids were used as the control of TRAIL plasmids. When the tumor size was 
approximately 150 mm3, H460 xenografts tumor-bearing nude mice were randomized to five 
groups (five mice per group): untreated control (PBS), DOTAP-LPD-GFP NPs, DOBP-LPD-
GFP NPs, DOTAP-LPD-TRAIL NPs and DOBP-LPD-TRAIL NPs. The mice received tail 
vein injections of treatments every other day for a total of 5 injections with a dose of 50 μg 
DNA/mouse (0.6 μmol of DOBP or DOTAP/mouse). Tumor volume and body weight were 
measured every day. Mice were sacrificed two days after the last injection, and serum was 
collected for hepatic and renal function analysis.
2.13. TUNEL assay and H&E staining
The tumor and major organs were collected and fixed with 4% paraformaldehyde in PBS 
overnight and processed with paraffin embedding by the UNC histology facility. Apoptosis 
of tumor cells was then explored by TdT-dependent dUTP-biotin nick end labeling 
(TUNEL) assay using an apoptosis detection kit (Promega, Madison, WI) according to the 
manufacturer’s instructions. All samples were observed with an Eclipse Ti-U inverted 
microscope (Nikon Corp., Tokyo, Japan) and quantified using Image J software based on the 
manufacturer’s instructions. The formalin-embedded tissues were stained by hematoxylin 
and eosin (H&E) to identify the pathological change of major organs.
2.14. Quantitative Real-time PCR (qPCR) assay
The total RNA of tumor tissues was extracted using RNeasy Kit (Qiagen, CA). The cDNA 
was reverse-transcribed with the First-Strand Synthesis System for qPCR (Invitrogen, NY). 
Then cDNA (~100 ng) was amplified using the Taqman® Universal Probes Supermix system 
(Biorad, CA) with Taqman® primer against human TRAIL (Hs00234355_ml, Invitrogen 
CA). Reactions were conducted with the 7500 Real-Time PCR System, and the 7500 
software was used to analyze the data. GAPDH (Taqman® primer against human GAPDH, 
hs02758991_g1) was utilized as the endogenous control.
2.15. In vitro and in vivo transfection of TRAIL DNA
To investigate the in vitro transfection of TRAIL DNA, H460 cells were grown until 80% 
confluent in six-well plates. Then DOBP-LPD-TRAIL NPs, DOTAP-LPD-TRAIL NPs and 
DOBP-LPD-GFP NPs were added to each well in the presence of OptiMEM medium with 
final concentration of 1 μg plasmid/mL. Medium was refreshed 4 h after transfection. The 
remaining cells were treated for another 48 h. The transfection efficiency of TRAIL was 
determined by Western-Blot analysis using primary antibody against human TRAIL (Prosci) 
and with GAPDH as a loading control. For in vivo transfection, the expression levels of 
TRAIL DNA in tumor tissues were determined by qPCR and Western-Blot assay, 
respectively.
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2.16. Statistical analysis
Student’s t-test and one-way analysis of variance (ANOVA) were utilized to analyze the 
differences of the groups, and P < 0.05 was considered statistically significant. Data were 
shown as mean ± SD.
3. Results and discussions
3.1. Rational design of 1,2-di-(9Z-octadecenoyl)-3-biguanide-propane (DOBP)
To test our hypothesis, a novel cationic lipid (DOBP) was designed and synthesized by using 
biguanide as the cationic head (Fig. 2). Oleic acid was coupled to the hydroxyl position of 
N-Boc-3-amino-glycerine, the Boc protection was then removed to obtain 1,2-di-(9Z-
octadecenoyl)-3-amino-propane (DOAP). Finally, Dicyandiamide was conjugated to the 
amino group of DOAP to obtain DOBP. DOBP was intended as a versatile lipid that could 
be applied as a gene carrier as well as an anticancer drug. As shown in Fig. S1, the NMR 
spectrum confirmed the successful synthesis of DOBP. With the disappearing of the peak of 
ammonium salt, the typical peaks of biguanide can be found around the δ value of 7 ppm.
3.2. Preparation of blank liposomes and LPD NPs
Both the blank liposomes (Lipo-DOBP and Lipo-DOTAP) and the LPD nano-formulations 
(DOBP-LPD-GFP NPs, DOBP-LPD-TRAIL NPs, DOTAP-LPD-GFP NPs and DOTAP-
LPD-TRAIL NPs) were prepared following a well-established protocol developed by our lab 
[15]. Dynamic light scattering (DLS) was utilized to determine their particle size and zeta 
potential. As shown in Table S1, the average diameter of Lipo-DOBP and Lipo-DOTAP was 
120–130 nm, and the zeta potential was determined to be ~50 mV. The particle size of LPD 
formulations was determined to be 140–150 nm with a slightly decreased positive zeta 
potential (~37 mV) due to the encapsulation of the negative charged polyplex core (−28.4 
mV). TEM images analyzing particle morphology confirmed the successful fabrication of 
LPD NPs (Fig. S2). Moreover, we further investigated the stability of the prepared LPD NPs 
in PBS (pH 7.4) supplemented with 5% of fetal bovine serum (FBS) for 12 h at 37 °C. As 
shown in Fig. S3, the prepared LPD NPs showed good stability with no significant variation 
of their mean diameter over a period of 12 h. Successfully formulating TRAIL plasmids into 
DOBP-LPD-TRAIL NPs suggested that this novel cationic lipid could be used for systemic 
gene delivery, due to its biguanide head group and structural similarity to DOTAP.
3.3. In vitro cytotoxicity of blank liposomes
To test the anticancer potency of DOBP, the in vitro cytotoxicity of metformin, Lipo-DOBP 
and Lipo-DOTAP was evaluated in H460 cells. As shown in Fig. 3, metformin showed 
almost no cytotoxicity at the dose tested, but significant cytotoxicity of metformin could be 
observed at a higher dose (data not shown). Interestingly, Lipo-DOBP showed the highest 
cytotoxicity when compared with both metformin and Lipo-DOTAP. Notably, Lipo-DOTAP 
also showed some cytotoxicity at high dose (2 mM) due to its non-specific antitumor activity 
[18]. Metformin is different from the conventional cytotoxic agents (e.g. paclitaxel and 
doxorubicin), the lower in vitro cytotoxicity of metformin corresponds to its good safety 
profile, as this drug is used in the clinics at very high doses due to very low toxicity [10]. By 
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contrast, “formulating” the biguanide (DOBP) into the nano-sized liposomes greatly 
enhanced its cytotoxicity to tumor cells. Additionally, the in vitro cytotoxicity of Lipo-
DOBP and Lipo-DOTAP were evaluated in human fetal lung fibroblast cells (MRC-5 cells). 
As shown in Fig. S4, within the same concentration range of the cytotoxicity test in H460 
cells, Lipo-DOBP and Lipo-DOTAP showed much less cytotoxicity in MRC-5 cells than in 
H460 cells, probably due to the fast proliferation of the latter.
3.4. Cellular uptake and intracellular trafficking of DOBP-LPD NPs
The cellular uptake and dynamic intracellular trafficking of DOBP-LPD NPs were 
investigated using confocal microscopy. The function of anisamide (AA) as targeting ligand 
were also evaluated. Cy5-labelled DNA (Cy5-DNA, shown as magenta) and hydrophobic 
dye DiI incorporated into Lipo-DOBP (shown as red) were utilized to track the intracellular 
distribution of DNA and carrier, respectively. H460 cells were incubated with the double-
labelled DOBP-LPD NPs (with or without AA) for different time periods as specified in Fig. 
4. The cell samples were co-stained for multiple organelles, including cell nuclei (with 
Hoechst, blue) and lysosomes (with LysoTracker Green, green). Tracking the double-
labelled NPs relative to these cell organelles provided information how the plasmid delivered 
by DOBP-LPD NPs were transported through the cytoplasm into the nucleus. As shown in 
Fig. 4B and D, the overall internalization of lipid vector and plasmid were increased 
gradually with time. As expected, AA could significantly facilitate the cellular uptake of 
LPD NPs, which provides the basic rationale for choosing AA as a targeting ligand for in 
vivo therapeutic application. The overall fluorescence (both Cy5-DNA and DiI) of cells 
incubated with non-targeted NPs were relatively weak over the course of the time monitored. 
The accumulation of NPs into lysosomes were observed only at 6 h after incubation. The 
binding and internalization process occurred rapidly in the AA-DOBP-LPD NPs incubated 
cells. As shown in Panel C and E, both DiI and Cy5-DNA carried by AA-DOBP-LPD NPs 
were accumulated into the lysosome (co-localized with LysoTracker, shown as yellow and 
white, respectively) rapidly within 0.5 h of incubation. The co-localization of Cy5-DNA and 
DiI suggested that the NPs remained intact at this time point. The endosomal release of AA-
DOBP-LPD NPs was observed at 2 h after incubation, as large amount of DiI was scattered 
throughout the cytoplasm. As expected, dissociation of plasmid from the lipid vector 
occurred upon endosomal release (Panel F, 2 h). As the time increased, the dissociated 
plasmids were gradually translocated into the nucleus (panel D–F, 6 h), most likely due to 
the nucleus targeting function of protamine [19]. Overall, the intracellular trafficking study 
suggested that the novel cationic lipid DOBP and the targeting ligand AA, could efficiently 
enable the internalization, endosomal escape of the LPD NPs, allowing plasmid to dissociate 
from the lipid and effectively transport into the nucleus for transcription and gene 
expression.
3.5. In vivo antitumor activity of blank liposomes
The in vivo antitumor efficacy of metformin, Lipo-DOBP, and Lipo-DOTAP was initially 
evaluated in nude mice bearing H460 xenograft tumors. Metformin and Lipo-DOBP were 
administrated intravenously every other day for a total of 5 injections at a dose equivalent to 
5 mg/kg of metformin, and Lipo-DOTAP was administrated at an equivalent molar dose of 
Lipo-DOBP. Mice that were dosed only with PBS were used as a control. As shown in Fig. 
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5, both Lipo-DOBP and metformin showed significant antitumor efficacy, with a distinctly 
delayed tumor progression. Lipo-DOTAP were also able to somewhat suppress tumor 
growth, due to the non-specific antitumor activity of DOTAP which has been reported before 
[18]. Notably, despite the low cytotoxicity of metformin in vitro, it demonstrated significant 
antitumor activity in vivo. Indeed, distinguished from the conventional cytotoxic agents, 
metformin delays the tumor growth and proliferation via acting on cell signaling pathways 
[10].
A TUNEL assay (Fig. 5D and E) demonstrated significant tumor cell apoptosis in mice 
treated with metformin, Lipo-DOBP and Lipo-DOTAP. Both metformin and Lipo-DOBP 
induced higher rates of apoptosis in tumors over Lipo-DOTAP. Importantly, no significant 
change in body weight was observed across all mouse populations (Fig. 6A). The 
hematological parameters, aspartate aminotransferase (AST), alanine aminotransferase 
(ALT) levels, blood urea nitrogen (BUN) and creatinine, showed no indication of toxicity 
(Fig. 6B). Moreover, the in vitro apoptosis and necrosis studies indicated that both Lipo-
DOBP and Lipo-DOTAP showed much less late apoptosis and necrosis when compared with 
a frequently-used cationic polymer PEI (Fig. S5). And no noticeable histological changes 
were observed in H&E-stained tissue sections of major organs (Fig. S7). These results 
suggest that DOBP with intrinsic antitumor activity elicited no significant off-target 
toxicities to major organs and tissues.
3.6. Antitumor mechanism of DOBP
As described before, Lipo-DOBP exhibited comparable in vivo antitumor efficacy with 
metformin. We then investigated the antitumor mechanism of DOBP. Since the C–N bond 
between the biguanide moiety is highly stable and the biguanide group is the key point for 
the antitumor activity of metformin [10], we inferred that the biguanide moiety on DOBP 
directly induced anti-tumor efficacy without being cleaved off. Several studies have 
indicated that metformin inhibits cancer cells growth by activating the AMP-activated 
protein kinase (AMPK) and inhibiting the mammalian target of rapamycin (mTOR) 
pathways [20,21]. AMPK is a metabolic tumor suppressor that affects glucose and lipid 
metabolism, and mTOR is a downstream effector of AMPK. The degree of phosphorylation 
of AMPK and mTOR plays a crucial role in the proliferation and survival of cancer cells 
[22,23]. Moreover, a recent study published by our group demonstrated that a non-cleavable 
biguanide group (PolyMet) could directly induce tumor apoptosis through activation of the 
AMPK and inhibiting the mTOR pathways [11]. Therefore, to address the intrinsic 
antitumor activities of the biguanide containing-DOBP, the regulation of these two pathways 
were evaluated by Western-Blot assay. As shown in Fig. 5C, AMPK-α was phosphorylated 
at a much higher rate in tumor tissues that was treated with metformin and Lipo-DOBP than 
with PBS and Lipo-DOTAP. In contrast, mTOR phosphorylation was down-regulated in 
metformin and Lipo-DOBP treated tissues. The Western blot results indicated that DOBP 
followed a similar antitumor mechanism as metformin, and further confirmed our hypothesis 
that the biguanide head of DOBP made it a versatile cationic lipid with intrinsic antitumor 
activity.
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3.7. Pharmacokinetics and biodistribution of LPD NPs
Pharmacokinetics and biodistribution studies of DOBP-LPD NPs and DOTAP-LPD NPs 
were evaluated in nude mice with 3H-cholesterol as a label. As shown in Fig. S6, DOBP-
LPD NPs and DOTAP-LPD NPs demonstrated similar pharmacokinetic behaviors and 
biodistribution in major organs. These results could be attributed to the similar chemical 
structure of DOBP with DOTAP and the same LPD nano-formulation. Additionally, most 
NPs were accumulated in liver and spleen due to the abundant blood and the presence of 
reticuloendothelial system (RES).
3.8. In vivo antitumor activity of LPD NPs
Lipo-DOBP showed significant antitumor activity in vitro and in vivo. We then investigated 
the anticancer efficacy of TRAIL-encapsulating LPD NPs modified with DSPE-PEG-AA. In 
this study, GFP plasmids were used as the control DNA. The in vivo antitumor efficacy of 
LPD formulations (DOBP-LPD-GFP NPs, DOTAP-LPD-GFP NPs, DOBP-LPD-TRAIL 
NPs and DOTAP-LPD-TRAIL NPs) was evaluated in nude mice bearing H460 xenograft 
tumors, with PBS injections as a control. This study was performed on relatively large 
tumors (over 150 mm3). Treatment was administered via tail vein injections every other day 
for a total of 5 injections with a dose of 50 μg DNA/mouse. As shown in Fig. 7, DOBP-
LPD-GFP NPs, DOTAP-LPD-TRAIL NPs and DOBP-LPD-TRAIL NPs all demonstrated 
distinct antitumor activity, but DOBP-LPD-TRAIL NPs exhibited significant superiority 
over both DOBP-LPD-GFP NPs and DOTAP-LPD-TRAIL NPs. This is likely due to the 
intrinsic anticancer activity of DOBP combined with TRAIL-induced apoptosis. Activation 
of AMPK signaling pathway could significantly sensitize TRAIL-induced apoptosis of 
human tumor cells [12–14]. As shown earlier (Fig. 5C), AMPK activation was observed in 
Lipo-DOBP treated groups. In addition, DOTAP-LPD-GFP NPs were unable to significantly 
suppress tumor growth when compared with PBS group. These results indicated that DOBP, 
a versatile cationic lipid, could be used as a new cationic lipid with intrinsic antitumor 
activity to facilitate the gene therapy of TRAIL DNA.
A TUNEL assay was used to quantify apoptosis in tumor tissues after treatment. As shown 
in Fig. 7D and E, DOBP-LPD-GFP NPs, DOTAP-LPD-TRAIL NPs and DOBP-LPD-
TRAIL NPs demonstrated significant tumor cell apoptosis in mice after treatment, and 
DOBP-LPD-TRAIL NPs showed distinct superiority over DOBP-LPD-GFP NPs and 
DOTAP-LPD-TRAIL NPs. In addition, no significant change in body weight was observed 
in any of the mice used in this study (Fig. 7C). The hematological parameters indicated no 
detectable damage (Fig. S8) and no noticeable histological changes were observed in H&E-
stained tissue sections of major organs (Fig. S9). These results indicated that DOBP-LPD-
TRAIL NPs, with combined antitumor activity of DOBP and TRAIL DNA, showed no 
significantly nonspecific toxicity to major organs and tissues.
3.9. In vitro and in vivo transfection of TRAIL DNA
To investigate the in vitro and in vivo transfection of TRAIL DNA, qPCR and Western-Blot 
assay were used to measure the gene expression in tumor tissues. As shown in Fig. 8, 
DOBP-LPD-TRAIL NPs and DOTAP-LPD-TRAIL NPs showed comparable TRAIL mRNA 
expression level. Consistently, these two formulations induced similar TRAIL protein 
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expression both in vitro and in vivo (Fig. S10). The enhanced TRAIL expression was seen 
over the background levels of endogenous TRAIL in the control groups. These results 
suggested that DOBP, with a very similar structure to DOTAP, transfected cells as efficiently 
as commercially available DOTAP. While DOBP-LPD-TRAIL NPs exhibited higher 
antitumor efficacy than that of DOTAP-LPD-TRAIL NPs, due to the intrinsic antitumor 
activity of gene carrier and the TRAIL-induced apoptosis in tumor cells. These results 
further confirmed our hypothesis that DOBP could be used as a versatile cationic carrier to 
facilitate gene therapy of TRAIL DNA.
4. Conclusions
Inspired by the antitumor activity of metformin, a novel cationic lipid (DOBP) with intrinsic 
antitumor activity was designed for systemic gene delivery in cancer therapy. For this new 
lipid, biguanide simultaneously acts as the cationic lipid for gene encapsulation and delivery, 
as well as the pharmacologically active treatment for cancer. DOBP showed comparable 
capacity of gene transfection with DOTAP, and exhibited potent antitumor activity in vitro 
and in vivo with a similar anticancer mechanism to metformin. As a result, DOBP-LPD-
TRAIL NPs demonstrated distinct superiority in antitumor efficacy over DOTAP-LPD-
TRAIL NPs due to the intrinsic antitumor activity of biguanide and the TRAIL-induced 
apoptosis in tumor cells. Therefore, DOBP, a novel versatile cationic lipid, provides a 
promising platform for systemic delivery of gene.
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Fig. 1. 
(A) Chemical structures of DOTAP, metformin and DOBP. (B) Schematic illustration of 
LPD-TRAIL NPs.
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Fig. 2. 
Synthesis routes of DOBP. (i) DCC, DMAP, r.t.; (ii) Hydrochloride acid solution in 1,4-
dioxane; and (iii) FeCl3.
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Fig. 3. 
Representative dose-response curves of the MTT assays against H460 cells.
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Fig. 4. 
In vitro cellular uptake and intracellular trafficking of AA-DOBP-LPD NPs and AA-free 
DOBP-LPD NPs. (A) DIC/DAPI/Lysotracker Green. (B) DiI. (C) DiI/DAPI/Lysotracker 
Green. (D) Cy5 DNA. (E) Cy5 DNA/DAPI/Lysotracker Green. (F) Cy5 DNA/DiI. Scale bar 
represents 10 μm. (For interpretation of the references to color in this figure legend, the 
reader is referred to the web version of this article.)
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Fig. 5. 
In vivo antitumor activity of blank liposomes (n = 5). (A) Tumor growth curves. (B) Tumor 
burden, the weight of tumors was divided by the average body weight of mice. (C) Western 
blot results. (D) TUNEL assay quantitative results of tumor sections treating with different 
formulations by Image J software. (E) TUNEL assay pictures of tumor sections treating with 
different formulations. The data are presented as means ± SD, *P < 0.05 and **p < 0.01. 
Scale bar represents 500 μm.
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Fig. 6. 
(A) Body weight changes and (B) hepatic and renal function indicators of mice bearing 
H460 tumor xenografts after treatment with blank liposomes (n = 5). No significant 
difference.
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Fig. 7. 
In vivo antitumor activity of LPD NPs (n = 5). (A) Tumor growth curves. (B) Tumor burden, 
the weight of tumors was divided by the average body weight of mice. (C) Body weight 
changes. (D) TUNEL assay quantitative results of tumor sections treating with different 
formulations by Image J software. (E) TUNEL assay pictures of tumor sections treating with 
different formulations. The data are presented as means ± SD, *P < 0.05 and **p < 0.01. 
Scale bar represents 500 μm.
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Fig. 8. 
In vivo transfection of TRAIL plasmids. Difference from PBS group, **P < 0.01.
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